Cue Biopharma, Inc. (CUE) income statement
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$2.83−11.27 (-79.93%)
Close on Nov 17, 2026Market cap $20.56MP/E –Yield –
Cue Biopharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -262.0%
- Net margin
- -435.8%
- Return on equity, FY2025
- -121.1%
Financial strength
- Current ratio
- 1.25
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 82.0%
Valuation
- P/E ratio
- –
- Price to sales
- 0.55
- Price to book
- 8.90
- Dividend yield
- –
See a number that looks wrong?